SCHEMBL440817

SCHEMBL440817

O=C(NCCNC(=O)N1CCN(c2ccccc2)CC1)c1cn(-c2ccccc2)nc1C(F)(F)F

nearest known ligand 0.61

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 15/20 0.61
DRD2 P14416 4/20 0.51
DRD3 P35462 4/20 0.51
KDM5B Q9UGL1 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL437998 0.93 DGAT1 (0.62) DGAT1DRD2DRD3KDM5B
SCHEMBL440809 0.91 DGAT1 (0.60) DGAT1KDM5B
SCHEMBL463686 0.91 DGAT1 (0.55) DGAT1DRD2DRD3
Hydrochloric Acid SCHEMBL4930036 0.90 DGAT1 (0.61) DGAT1KDM5B
SCHEMBL439865 0.90 DGAT1 (0.57) DGAT1
SCHEMBL462632 0.89 DGAT1 (0.61) DGAT1DRD2DRD3
SCHEMBL463160 0.89 DGAT1 (0.54) DGAT1DRD2DRD3
SCHEMBL437406 0.88 DGAT1 (0.59) DGAT1KDM5B
SCHEMBL440581 0.88 DGAT1 (0.60) DGAT1KDM5B
SCHEMBL438636 0.87 DGAT1 (0.58) DGAT1KDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065196-A1 AMIDE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-15 US disclosed
US-20120065196-A1 AMIDE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065196-A1 AMIDE COMPOUNDS DGAT2, DGAT1, DLAT DGAT1 2/4885DRD2 3020/4885DRD3 3402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.